New Delhi, March 6:
Everest Organics said today that the US health regulator has inspected its Aroor plant and has made one observation.
“The United States Food and Drug Administration (USFDA) inspected our facility at village Aroor from February 27, 2017 to March 3, 2017. There is only one observation,” Everest Organics said in a filing to BSE.
The pharma firm believes that this is of minor nature and corrective and preventive action for this observation will be presented to the regulator shortly, it added.
Everest Organics develops, manufactures and markets a broad range of APIs and bulks drugs intermediates. It exports the products to over 20 countries.
Shares of Everest Organics were today trading 4.84 per cent higher at Rs 72.60 apiece on the BSE.
(This article was published on March 6, 2017)
Get more of your favourite news delivered to your inbox
Please enter your email. Thank You.
Newsletter has been successfully subscribed.